AOD-9604 vs MOTS-c: Comparing Two Unproven Research Peptides
Medically reviewed by Medical Advisory Board Last reviewed 2026-07-20
Neither is FDA-approved, and neither has controlled human trial data for its main claim — here's how they actually differ
AOD-9604 (a GH-fragment peptide) and MOTS-c (a mitochondrial-derived peptide) are both popular in research-chemical circles, both lack FDA approval, and both lack a positive controlled human trial for their headline claim. But they target different mechanisms — lipolysis vs. mitochondrial signaling and insulin sensitivity — and are used for different goals.
This article is for informational purposes only and is not medical advice. Consult a physician before using any research peptide.
AOD-9604 and MOTS-c are both frequently recommended in the same biohacking and longevity communities, which leads to a natural question: how do they actually differ, and is one better supported by evidence than the other? Neither has an FDA approval or a positive Phase III human trial behind it, but the honest comparison still has real distinctions worth understanding before considering either.
Want expert help with your metabolic health?
We can match you with a metabolic-medicine specialist who understands this area — so you get the right doctor, not just any doctor.
Book An Appointment With A Specialist →AOD-9604 vs MOTS-c at a Glance
AOD-9604 and MOTS-c share a regulatory status — neither is FDA-approved — but they come from different biology and target different outcomes.| Dimension | AOD-9604 | MOTS-c |
|---|---|---|
| Origin | Synthetic fragment (amino acids 176-191) of human growth hormone | Naturally occurring peptide encoded in mitochondrial DNA (12S rRNA gene) |
| Proposed mechanism | Isolated lipolytic (fat-burning) activity of GH, without GH's growth-promoting effects | AMPK activation — the same cellular energy-sensing pathway engaged by exercise and metformin |
| Primary claim | Targeted fat loss | Improved insulin sensitivity; informally called an "exercise mimetic" |
| Human RCT evidence | Phase III trial completed and failed (no significant weight loss vs. placebo) | No large controlled human trial published; evidence is mostly animal studies and human observational data |
| FDA status | Not approved; GRAS food-ingredient status only (2020) | Not approved; no regulatory food or drug status |
| Access | Unregulated research chemical | Unregulated research chemical |
| Typical community use | Fat loss, often stacked with GH secretagogues | Metabolic/longevity framing, often stacked with NAD+ or exercise-focused protocols |
The Key Difference: What Kind of Evidence Gap Each Has
AOD-9604 and MOTS-c have different — not equal — evidence gaps. AOD-9604 was actually tested in a Phase III randomized controlled trial for its main claim (obesity/weight loss) and failed to beat placebo — a negative result from a real trial. MOTS-c has not yet had a comparable large controlled human trial run at all; its evidence base is animal studies (showing improved insulin sensitivity and reduced diet-induced obesity in mice) plus small human observational studies correlating circulating MOTS-c levels with age and exercise.
In practice: AOD-9604's claim has been tested in humans and did not hold up. MOTS-c's claim has not yet been rigorously tested in humans either way — the absence of evidence is not the same as evidence of failure, but it also is not evidence of success.
Which Is the Better Researched Option?
Neither compound has an approved indication or a positive human trial, so "better researched" depends on what's being asked. If the question is fat loss specifically, AOD-9604's own trial data argues against it — see the full AOD-9604 review for evidence-based alternatives with actual trial support. If the question is metabolic/insulin-sensitivity support, MOTS-c's animal data is more encouraging than AOD-9604's human trial result, but it still falls short of the human RCT evidence available for options covered in our MOTS-c guide.
Can AOD-9604 and MOTS-c Be Combined?
Because the two target different pathways — lipolysis versus AMPK activation — some users stack them, reasoning the mechanisms are additive rather than redundant. No controlled trial has evaluated this specific combination, and given that neither compound has strong standalone human efficacy data, any reported result from stacking them cannot be attributed to either peptide with confidence.
Frequently Asked Questions
Is AOD-9604 or MOTS-c better supported by evidence?
Neither has FDA approval or strong human trial data. AOD-9604 was actually tested in a Phase III human trial and failed to beat placebo for weight loss. MOTS-c has not yet had a comparable large human trial — its evidence is mostly animal studies and small observational human data. Which is "better researched" depends on whether you weigh a negative human trial result or an absence of human trial data as the bigger gap.
Do AOD-9604 and MOTS-c work the same way?
No. AOD-9604 is an isolated fragment of growth hormone believed to carry a fat-burning (lipolytic) effect. MOTS-c is a mitochondrial-derived peptide proposed to activate AMPK, the same cellular energy-sensing pathway triggered by exercise and metformin. They target different biological mechanisms and different primary claims — fat loss versus insulin sensitivity and metabolic signaling.
Can you stack AOD-9604 and MOTS-c?
Some users combine them because they act on different pathways, but no controlled human trial has tested this specific combination. Since neither peptide has strong standalone human efficacy evidence, any result from stacking them is anecdotal rather than trial-supported.
Is either AOD-9604 or MOTS-c FDA-approved?
No. Neither has FDA approval for any use. AOD-9604 was granted GRAS (Generally Recognized as Safe) status as a food ingredient in 2020, which is a narrow oral-safety classification, not a drug approval. MOTS-c has no FDA status of any kind and is sold strictly as a research chemical.
Topic updates
Get the weekly peptide roundup
Peptide therapy, GLP-1s, growth hormone peptides, healing peptides, safety notes, and comparison guides.
Check Where You Stand
Take our free health assessment to understand your metabolic, hormonal, and recovery risk factors — and get personalized recommendations.
Take the Free Assessment →Free · Takes 5 minutes · Instant results
Related Comparisons
-
AOD-9604 vs HGH Fragment 176-191: Are They the Same Peptide?
AOD-9604 vs HGH Fragment 176-191: naming confusion, history, and what the evidence shows.
-
AOD-9604 vs Tesamorelin: Which Fat-loss Peptide Has Real Evidence?
AOD-9604 vs tesamorelin: failed obesity trial vs FDA-approved visceral-fat peptide.
-
AOD-9604 vs Tirzepatide: Research Peptide vs FDA-approved Weight Loss Drug
AOD-9604 vs tirzepatide: unproven research peptide vs FDA-approved GLP-1 weight-loss drug.
See more related comparisons
-
AOD-9604: the Fat-loss Peptide That Failed Phase III — and What Works Instead
AOD-9604: the GH fragment that failed Phase III, why it's still sold, and what actually works for fat loss.
-
MOTS-c Peptide: Mitochondrial Research and Metabolism
MOTS-c: the mitochondrial-derived peptide studied for insulin sensitivity and metabolism.